Gastric cancer is one of the most common cancers and one of the most frequent causes of cancer-related deaths. The incidence, diagnostic studies, and therapeutic options have undergone important changes in the last decades, but the prognosis for gastric cancer patients remains poor, especially in more advanced stages. Surgery is the mainstay of treatment of this disease, even if it is associated with a high rate of locoregional and distant recurrence. There is ongoing debate regarding the role of adjuvant treatment In advanced disease, palliation of symptoms, rather than cure, is the primary goal of patient management. Several combination therapies have been developed and have been examined in phase III trials; however, in most cases, they have failed to demonstrate a survival advantage over the reference arm. This review summarizes the most important recommendations for the management of patients with gastric cancer
Gastric Cancer / V. Catalano, R. Labianca, G. Beretta, G. Gatta, F. de Braud, E. Van Cutsem. - In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. - ISSN 1040-8428. - 54:3(2005 Jun), pp. 209-241.
|Parole Chiave:||Lymph-node metastasis; prospective randomized-trial; quality-of-life; carcinoembryonic antige levels; helicobacter-pylori infection; cooperative-oncology-group; phase-III trial; comparing adjuvant fluorouracil; advanced esophagogastric cancer; intensive weekly chemotherapy|
|Settore Scientifico Disciplinare:||Settore MED/06 - Oncologia Medica|
|Data di pubblicazione:||giu-2005|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1016/j.critrevonc.2005.01.002|
|Appare nelle tipologie:||01 - Articolo su periodico|